ARDS, Human Clinical Trial
— LIPSOfficial title:
Early LIght Sedation Pressure Support in ARDS Patients
Verified date | March 2022 |
Source | University Hospital, Lille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sedation may have many drawbacks in ICU patients: cardiovascular, neurologic, muscular. Light sedation and Pressure Support ventilation is feasible in ARDS patients. However spontaneous breathing can lead to high transpulmonary pressure. The goal of the study is to measure transpulmonary pressure before sedation decrease and after stabilization. The main endpoint is transpulmonary pressure less than 24 cmH2O.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ARDS (Berlin definition) - social insurance Exclusion Criteria: - neuromuscular disorders - pregnancy - need for muscular paralysis - need for deep neurosedation - more than 24hrs of artificial ventilation - cystic fibrosis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | transpulmonary pressure at early stabilization of patient | transpulmonary pressure (Paw - Peso < 24 cmH2O) | when patient is conscious and stable (no modification of ventilator settings) generally within 2 hours | |
Secondary | oxygenation modification | PaO2/FiO2 | stabilization of ventilator settings; 1hour after stabilization of ventilator settings | |
Secondary | arterial pressure modification | Mean arterial pressure | stabilization of ventilator settings; 1hour after stabilization of ventilator settings | |
Secondary | Heart rate modification | heart rate | stabilization of ventilator settings;1hour after stabilization of ventilator settings | |
Secondary | vasopressor dose modification | vasopressor dose in norepinephrine equivalent | stabilization of ventilator settings ; 1hour after stabilization of ventilator settings | |
Secondary | acquired neuromyopathy | MRC <48/60 | ICU discharge, an average 16 days | |
Secondary | muscular volume decrease | quadriceps volume assessed by echography | at 24 hours; at day of extubation; ICU discharge, an average 16 days | |
Secondary | ventilator free days | ventilator free days until day 28 | during the first 28 days | |
Secondary | delirium in ICU | CAM-ICU is a valid and reliable delirium assessment tool recommended by the Society of Critical Care Medicine (SCCM) in its 2013 Pain, Agitation and Delirium (PAD) guidelines. the presence of delirium is confirmed in the presence of criteria 1, 2 and 3 or 4. | ICU discharge, an average 16 days | |
Secondary | change of the functional respiratory parameters from baseline at 6 months | vital capacity, total pulmonary capacity, | at 6 months | |
Secondary | PTSD | post traumatic stress disorder impact of event scale > 33 tems are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") and the total score (ranging from 0 to 88) | at 6 months | |
Secondary | number of auto extubation | whatever until ICU discharge, an average 16 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|